Animal models alone are no longer sufficient to unravel the complexity of diseases involving the immune system, central nervous system (CNS), cancer, or ageing, which limits the development of effective new therapies. Traditional in vitro models also fall short — they fail to accurately reproduce the immune and vascular systems, drug biodistribution, and critical physiological interfaces such as the blood–brain barrier. At the same time, building reliable and predictive AI models for drug discovery and patient-tayloring purposes requires access to vast amounts of high-quality, biologically relevant data — integrating both omic and phenotypic dimensions to truly capture human complexity.
Our proprietary, automatable, and scalable patient-specific CNS models, based on induced pluripotent stem cells (iPSC)-derived vascularized and perfused organoid assembloids, enable simultaneous internal perfusion and tissue maturation. These advanced systems provide direct access to longitudinal multimodal data — including imaging, electrophysiological recordings, and bioanalytical omics from both tissue and liquid biopsies — delivering a comprehensive view of human brain function and response.
Due to the exceptional complexity of the brain, our in vitro technologies are designed to faithfully mimic its key features—integrating physiologically and physiopathological relevant structures for the vasculature and the immune system within the CNS environment.
By integrating our proprietary patient-specific in vitro data with corresponding clinical, bioanalytical and imaging, datasets within our MIMIR Platform to generate a unique AI foundation model, we target unprecedented biological realism and analytical depth — reducing time to market, lowering R&D costs, and accelerating the discovery of therapies for devastating conditions in urgent need of solutions.
Animal models alone are no longer sufficient to unravel the complexity of diseases involving the immune system, central nervous system (CNS), cancer, or ageing, which limits the development of effective new therapies. Traditional in vitro models also fall short — they fail to accurately reproduce the immune and vascular systems, drug biodistribution, and critical physiological interfaces such as the blood–brain barrier. At the same time, building reliable and predictive AI models for drug discovery and patient-tayloring purposes requires access to vast amounts of high-quality, biologically relevant data — integrating both omic and phenotypic dimensions to truly capture human complexity.
Our proprietary, automatable, and scalable patient-specific CNS models, based on induced pluripotent stem cells (iPSC)-derived vascularized and perfused organoid assembloids, enable simultaneous internal perfusion and tissue maturation. These advanced systems provide direct access to longitudinal multimodal data — including imaging, electrophysiological recordings, and bioanalytical omics from both tissue and liquid biopsies — delivering a comprehensive view of human brain function and response.
Due to the exceptional complexity of the brain, our in vitro technologies are designed to faithfully mimic its key features—integrating physiologically and physiopathological relevant structures for the vasculature and the immune system within the CNS environment.
By integrating our proprietary patient-specific in vitro data with corresponding clinical, bioanalytical and imaging, datasets within our MIMIR Platform to generate a unique AI foundation model, we target unprecedented biological realism and analytical depth — reducing time to market, lowering R&D costs, and accelerating the discovery of therapies for devastating conditions in urgent need of solutions.
SIREN: 931797674
HEADQUARTERS
149 Avenue du Maine
75014 Paris, France, EU
LABORATORIES
Spartners – Servier/Biolabs Innovation Labs
22 Route 128
91190 Gif-sur-Yvette, France, EU
Acknowledgements:
